{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:33:53Z","timestamp":1790645633190,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Funds of China","doi-asserted-by":"publisher","award":["81500705"],"award-info":[{"award-number":["81500705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s13300-019-0644-0","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T15:02:28Z","timestamp":1563462148000},"page":"1801-1809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Frequency and Risk Factors for Neovascular Glaucoma After Vitrectomy in Eyes with Diabetic Retinopathy: An Observational Study"],"prefix":"10.1007","volume":"10","author":[{"given":"Xu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"644_CR1","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.2337\/diacare.27.10.2540","volume":"27","author":"DS Fong","year":"2004","unstructured":"Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540\u201353.","journal-title":"Diabetes Care"},{"key":"644_CR2","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1167\/iovs.12-10367","volume":"53","author":"Y Wakabayashi","year":"2012","unstructured":"Wakabayashi Y, Usui Y, Okunuki Y, et al. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. Investig Ophthalmol Vis Sci. 2012;53:6403\u201310.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"644_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/IJG.0b013e31824d514a","volume":"22","author":"A Goto","year":"2013","unstructured":"Goto A, Inatani M, Inoue T, et al. Frequency and risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. J Glaucoma. 2013;22:572\u20136.","journal-title":"J Glaucoma"},{"key":"644_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1755-3768.1988.tb08544.x","volume":"66","author":"P Summanen","year":"1988","unstructured":"Summanen P. Neovascular glaucoma following vitrectomy for diabetic eye disease. Acta Ophthalmol (Copenh). 1988;66:110\u20136.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"644_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0161-6420(84)34292-0","volume":"91","author":"M Ehrenberg","year":"1984","unstructured":"Ehrenberg M, McCuen BW, Schindler RH, Machemer R. Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology. 1984;91:321\u20135.","journal-title":"Ophthalmology"},{"key":"644_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.preteyeres.2004.12.001","volume":"24","author":"SS Hayreh","year":"2005","unstructured":"Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24:493\u2013519.","journal-title":"Prog Retin Eye Res"},{"key":"644_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0161-6420(85)34015-0","volume":"92","author":"GW Blankenship","year":"1985","unstructured":"Blankenship GW, Machemer R. Long-term diabetic vitrectomy results. Report of 10\u00a0year follow-up. Ophthalmology. 1985;92:503\u20136.","journal-title":"Ophthalmology"},{"key":"644_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02169815","volume":"227","author":"J Oldendoerp","year":"1989","unstructured":"Oldendoerp J, Spitznas M. Factors influencing the results of vitreous surgery in diabetic retinopathy. I. Iris rubeosis and\/or active neovascularization at the fundus. Graefes Arch Clin Exp Ophthalmol. 1989;227:1\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"644_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF01203852","volume":"87","author":"P Sima","year":"1994","unstructured":"Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol. 1994;87:223\u201332.","journal-title":"Doc Ophthalmol"},{"key":"644_CR10","doi-asserted-by":"publisher","first-page":"e6263","DOI":"10.1097\/MD.0000000000006263","volume":"96","author":"JW Kwon","year":"2017","unstructured":"Kwon JW, Jee D, La TY. Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. Medicine (Baltimore). 2017;96:e6263.","journal-title":"Medicine (Baltimore)"},{"key":"644_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000309199","volume":"184","author":"M Zirm","year":"1982","unstructured":"Zirm M. Protein glaucoma\u2013overtaxing of flow mechanisms? Preliminary report. Ophthalmologica. 1982;184:155\u201361.","journal-title":"Ophthalmologica"},{"key":"644_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0161-6420(02)01269-1","volume":"110","author":"WV Delaney","year":"2003","unstructured":"Delaney WV. Evidence-based recommendations for neovascular glaucoma. Ophthalmology. 2003;110:2 (author reply 2\u20133).","journal-title":"Ophthalmology"},{"key":"644_CR13","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0161-6420(96)30511-3","volume":"103","author":"I Dielemans","year":"1996","unstructured":"Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study. Ophthalmology. 1996;103:1271\u20135.","journal-title":"Ophthalmology"},{"key":"644_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S0161-6420(97)30247-4","volume":"104","author":"P Mitchell","year":"1997","unstructured":"Mitchell P, Smith W, Chey T, Healey PR. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology. 1997;104:712\u20138.","journal-title":"Ophthalmology"},{"key":"644_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF00159992","volume":"64","author":"CV Clark","year":"1986","unstructured":"Clark CV, Mapstone R. Systemic autonomic neuropathy in open-angle glaucoma. Doc Ophthalmol. 1986;64:179\u201385.","journal-title":"Doc Ophthalmol"},{"issue":"Pt 3","key":"644_CR16","first-page":"265","volume":"104","author":"R Mapstone","year":"1985","unstructured":"Mapstone R, Clark CV. The prevalence of autonomic neuropathy in glaucoma. Trans Ophthalmol Soc UK. 1985;104(Pt 3):265\u20139.","journal-title":"Trans Ophthalmol Soc UK"},{"key":"644_CR17","first-page":"133","volume":"98","author":"R Klein","year":"2000","unstructured":"Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133\u201341 (discussion 141\u20133).","journal-title":"Trans Am Ophthalmol Soc"},{"key":"644_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1442-9071.2010.02295.x","volume":"38","author":"R Thapa","year":"2010","unstructured":"Thapa R, Paudyal G, Bernstein PS. Demographic characteristics, patterns and risk factors for retinal vein occlusion in Nepal: a hospital-based case\u2013control study. Clin Exp Ophthalmol. 2010;38:583\u201390.","journal-title":"Clin Exp Ophthalmol"},{"key":"644_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/archopht.126.5.692","volume":"126","author":"PR O\u2019Mahoney","year":"2008","unstructured":"O\u2019Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126:692\u20139.","journal-title":"Arch Ophthalmol"},{"key":"644_CR20","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2337\/diabetes.48.10.1899","volume":"48","author":"E Duh","year":"1999","unstructured":"Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999;48:1899\u2013906.","journal-title":"Diabetes"},{"key":"644_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1161\/hs0302.104619","volume":"33","author":"CJ Klijn","year":"2002","unstructured":"Klijn CJ, Kappelle LJ, van Schooneveld MJ, et al. Venous stasis retinopathy in symptomatic carotid artery occlusion: prevalence, cause, and outcome. Stroke. 2002;33:695\u2013701.","journal-title":"Stroke"},{"key":"644_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1034\/j.1600-0420.2000.078002173.x","volume":"78","author":"M Ino-ue","year":"2000","unstructured":"Ino-ue M, Azumi A, Yamamoto M. Ophthalmic artery blood flow velocity changes in diabetic patients as a manifestation of macroangiopathy. Acta Ophthalmol Scand. 2000;78:173\u20136.","journal-title":"Acta Ophthalmol Scand"},{"key":"644_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s004170050150","volume":"236","author":"H Helbig","year":"1998","unstructured":"Helbig H, Kellner U, Bornfeld N, Foerster MH. Rubeosis iridis after vitrectomy for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1998;236:730\u20133.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"644_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ajo.2005.02.052","volume":"140","author":"JO Mason 3rd","year":"2005","unstructured":"Mason JO 3rd, Colagross CT, Haleman T, et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. Am J Ophthalmol. 2005;140:231\u20135.","journal-title":"Am J Ophthalmol"},{"key":"644_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3129\/i08-007","volume":"43","author":"CM Yang","year":"2008","unstructured":"Yang CM, Su PY, Yeh PT, Chen MS. Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome. Can J Ophthalmol. 2008;43:192\u20138.","journal-title":"Can J Ophthalmol"},{"key":"644_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2017.08.013","volume":"183","author":"J Castillo","year":"2017","unstructured":"Castillo J, Aleman I, Rush SW, Rush RB. Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a randomized and controlled trial comparing interval variation. Am J Ophthalmol. 2017;183:1\u201310.","journal-title":"Am J Ophthalmol"},{"issue":"1571\u201380","key":"644_CR27","first-page":"1580.e1","volume":"115","author":"T Wakabayashi","year":"2008","unstructured":"Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(1571\u201380):1580.e1\u20133.","journal-title":"Ophthalmology"},{"key":"644_CR28","doi-asserted-by":"publisher","first-page":"e110531","DOI":"10.1371\/journal.pone.0110531","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Chen S, Jiang F, et al. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS One. 2014;9:e110531.","journal-title":"PLoS One"},{"key":"644_CR29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ophtha.2010.08.038","volume":"118","author":"HA El-Sabagh","year":"2011","unstructured":"El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology. 2011;118:636\u201341.","journal-title":"Ophthalmology"},{"key":"644_CR30","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/bjo.2010.189514","volume":"95","author":"LQ Zhao","year":"2011","unstructured":"Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011;95:1216\u201322.","journal-title":"Br J Ophthalmol"},{"key":"644_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/sj.eye.6702983","volume":"23","author":"K Ishikawa","year":"2009","unstructured":"Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond). 2009;23:108\u201311.","journal-title":"Eye (Lond)"},{"key":"644_CR32","doi-asserted-by":"publisher","first-page":"e0123449","DOI":"10.1371\/journal.pone.0123449","volume":"10","author":"P Jin","year":"2015","unstructured":"Jin P, Peng J, Zou H, et al. A 5-year prospective study of diabetic retinopathy progression in chinese type 2 diabetes patients with \u201cwell-controlled\u201d blood glucose. PLoS One. 2015;10:e0123449.","journal-title":"PLoS One"},{"key":"644_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/diacare.23.8.1084","volume":"23","author":"Diabetes Control and Complications Trial Research Group","year":"2000","unstructured":"Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000;23:1084\u201391.","journal-title":"Diabetes Care"},{"key":"644_CR34","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","journal-title":"Lancet"},{"key":"644_CR35","doi-asserted-by":"publisher","first-page":"RA138","DOI":"10.12659\/MSM.883260","volume":"18","author":"B Terelak-Borys","year":"2012","unstructured":"Terelak-Borys B, Skonieczna K, Grabska-Liberek I. Ocular ischemic syndrome\u2014a systematic review. Med Sci Monit. 2012;18:RA138\u201344.","journal-title":"Med Sci Monit"},{"key":"644_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0161-6420(84)34293-2","volume":"91","author":"GC Brown","year":"1984","unstructured":"Brown GC, Magargal LE, Schachat A, Shah H. Neovascular glaucoma. Etiologic considerations. Ophthalmology. 1984;91:315\u201320.","journal-title":"Ophthalmology"},{"key":"644_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40942-016-0051-x","volume":"2","author":"GB Rodrigues","year":"2016","unstructured":"Rodrigues GB, Abe RY, Zangalli C, et al. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016;2:26.","journal-title":"Int J Retina Vitreous"},{"key":"644_CR38","doi-asserted-by":"publisher","first-page":"e77864","DOI":"10.1371\/journal.pone.0077864","volume":"8","author":"Y Li","year":"2013","unstructured":"Li Y, Wang J, Chen Z, Tang X. Effect of hydrophobic acrylic versus hydrophilic acrylic intraocular lens on posterior capsule opacification: meta-analysis. PLoS One. 2013;8:e77864.","journal-title":"PLoS One"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-0644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-019-0644-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-0644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:42:34Z","timestamp":1724413354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-019-0644-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s13300-019-0644-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"19 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}